Nuclear Medicine Imaging of Prostate Cancer.
The new tracer Gallium-68 prostate-specific membrane antigen (Ga-68 PSMA) yields new promising options for the PET/CT diagnosis of prostate cancer (PCa) and its metastases. To overcome limitations of hybrid imaging, known from the use of choline derivatives, seems to be possible with the use of Ga-68 PSMA for PCa. The benefits of hybrid imaging with Ga-68 PSMA for PCa compared to choline derivatives shall be discussed in this article based on an overview of the current literature.Key Points:• Ga-68 PSMA PET/CT can achieve higher detection rates of PCa lesions than PET/CT performed with choline derivatives• The new tracer Ga-68 PSMA has the advantage of high specificity, independence of PSA-level and low nonspecific tracer uptake in surrounding tissue• The new tracer Ga-68 PSMA seems very suitable for MR-PET diagnosticCitation Format:• Schreiter V, Reimann C, Geisel D et al. Nuclear Medicine Imaging of Prostate Cancer. Fortschr Röntgenstr 2016; 188: 1037 - 1044.
Department of Radiology, Charité Universitätsmedizin Berlin, Germany.
V
V
Schreiter
Department of Radiology, Charité Universitätsmedizin Berlin, Germany.
C
C
Reimann
Department of Radiology, Charité Universitätsmedizin Berlin, Germany.
D
D
Geisel
Department of Nuclear Medicine, Charité Universitätsmedizin Berlin, Germany.
N F
NF
Schreiter
D004492:Edetic Acid / Q000031:analogs & derivatives*; D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D009367:Neoplasm Staging; D009842:Oligopeptides; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology*; D019275:Radiopharmaceuticals
D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D009842:Oligopeptides; D019275:Radiopharmaceuticals; C000718244:gallium 68 PSMA-11; D004492:Edetic Acid